Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients.
Saif
Muhammad Wasif
MW
Gastrointestinal Malignancies Program, Yale University School of Medicine, New Haven, Connecticut, USA. mws27@email.med.yale.edu
Elfiky
Aymen A
AA
D001741:Black or African American; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D005528:Foot / Q000473:pathology; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000208:ethnology; D006225:Hand / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000208:ethnology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010292:Paresthesia; D011743:Pyrimidines / Q000009:adverse effects* / Q000494:pharmacology; D012307:Risk Factors; D013577:Syndrome; D013939:Thymidine Phosphorylase; D013940:Thymidylate Synthase; D014481:United States; D044465:White People
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D011743:Pyrimidines; D013940:Thymidylate Synthase; D013939:Thymidine Phosphorylase